Presentation is loading. Please wait.

Presentation is loading. Please wait.

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

Published byHetty Blau Modified over 5 years ago

Similar presentations

Presentation on theme: "Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A"— Presentation transcript:

1 Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer 
Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A. Boyle, MD, PhD, Hans-Ulrich Schildhaus, MD, Xian Lu, PhD, Rafal Dziadziuszko, MD, PhD, Jacek Jassem, MD, PhD, Marileila Varella-Garcia, PhD, Lynn E. Heasley, PhD, Ashley A. Kowalewski, MS, Kim Ellison, MS, HTL (ASCP), Gang Chen, MD, PhD, Caicun Zhou, MD, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 7, Pages (July 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A–C, FGFR1, FGF2, and FGF9 protein expression in small-cell lung cancer (immunohistochemistry, 200× original magnification). A, Positive for cytoplasmic and membranous FGFR1 protein expression (H-score = 285). B, Positive for nuclear and cytoplasmic FGF2 protein expression (H-score = 160). C, Positive for nuclear and cytoplasmic FGF9 protein expression (H-score = 100); a–c, Negative for FGFR1, FGF2, and FGF9 protein expression (H-score = 0). FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; H-score, hybrid scoring system. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A–C, FGFR1, FGF2, and FGF9 mRNA in small-cell lung cancer (in situ hybridization, 200× original magnification). Brown dots in cells represent mRNA expression. A, FGFR1 mRNA ISH expression (score = 4); a, FGFR1 mRNA ISH no expression (score = 0). B, FGF2 mRNA ISH expression (score = 2). C, FGF9 mRNA ISH expression (score = 2). FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; mRNA, messenger RNA; ISH, in situ hybridization. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 FGFR1 gene amplification in small-cell lung cancer (silver in situ hybridization, 400× original magnification). A, FGFR1 signals are black; CEN8 signals are red in nuclei. FGFR1 amplification (ratio = 8); a, nonamplified FGFR1 (ratio = 1). FGFR, fibroblast growth factor receptor. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A"

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Vascular endothelial growth factor A and its two receptors in human preantral follicles from fetuses, girls, and women  Ronit Abir, Ph.D., Asangla Ao,

Vascular endothelial growth factor A and its two receptors in human preantral follicles from fetuses, girls, and women  Ronit Abir, Ph.D., Asangla Ao,
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
Expression of neurotrophin 3 and its tropomyosin-related kinase receptor C in human preantral follicles  Galia Oron, M.D., Asangla Ao, Ph.D., Or Friedman,

Expression of neurotrophin 3 and its tropomyosin-related kinase receptor C in human preantral follicles  Galia Oron, M.D., Asangla Ao, Ph.D., Or Friedman,
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Sunny Guin, PhD, Yuanbin Ru, PhD, Murry W

Sunny Guin, PhD, Yuanbin Ru, PhD, Murry W
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer  Hui Yu, MD, PhD, Cory Batenchuk, PhD,

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer  Hui Yu, MD, PhD, Cory Batenchuk, PhD,
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.
Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L
Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis 

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis 
Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,

Similar presentations

Ads by Google